Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Highlights
Lung cancer is responsible for around 1.8 million deaths per year worldwide and is widely the leading cause of cancer-related mortality.
The development of specific inhibitors is currently extending to less common oncogenic drivers (i.e., ROS1, MET, RET, NTRK, HER2, and BRAF) with an exponential growth of dedicated clinical trials.
While, individually, each of these drivers appears with low prevalence, altogether, they account for 15% of all lung cancer cases, thereby affecting a large population of patients worldwide.
Similar to what is observed with most targeted therapies directed against an oncogenic driver, the initial clinical response to targeted kinase inhibitors is almost always temporary and acquired resistance to these drugs invariably emerges, restricting their clinical utility.
The…